Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002014925 | SCV002266639 | pathogenic | not provided | 2024-09-29 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1443 of the ABCA4 protein (p.Arg1443Cys). This variant is present in population databases (rs533422156, gnomAD 0.03%). This missense change has been observed in individual(s) with clinical features of Stargardt disease (internal data). ClinVar contains an entry for this variant (Variation ID: 1476832). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt ABCA4 protein function with a positive predictive value of 95%. This variant disrupts the p.Arg1443 amino acid residue in ABCA4. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15161829, 20404325, 22661472, 23419329, 23982839). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Fulgent Genetics, |
RCV005025567 | SCV005657312 | likely pathogenic | Cone-rod dystrophy 3; Age related macular degeneration 2; Severe early-childhood-onset retinal dystrophy; Retinitis pigmentosa 19 | 2024-05-08 | criteria provided, single submitter | clinical testing | |
| Institute of Human Genetics, |
RCV004816862 | SCV005072462 | uncertain significance | Retinal dystrophy | 2018-01-01 | no assertion criteria provided | clinical testing |